Revolution Medicines Inc. (RVMD) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Revolution Medicines Inc. (NASDAQ: RVMD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $191.31 (+0.55% 1D, market cap $40.78B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RVMD ranks #222 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), RVMD carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.6%. By comparison, BIIB (Biogen Inc.) holds a B grade (74/100 RQD, P/E 28.5x, ROIC 6.4%, cap $36.90B) and ARGX (argenx SE) posts a C grade (63/100 RQD, P/E 32.8x, ROIC 9.9%, cap $55.72B). Among the 5-stock peer group, BIIB leads on earnings multiple (28.5x) while ARGX leads on capital efficiency (9.9% ROIC).
Per RVMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001628171), Revolution Medicines Inc. generated $0 in revenue, -$1.13B in net income, and -$913.7M in free cash flow against $2.35B in total assets and $325.4M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
20D Institutional Volume Accumulation (±9.5% realized swing band)
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
Even with a 55/100 (D+) score, RVMD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Dilution Drag (+1.92% YoY Shares) — any gross margin slip below 15.0% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($198.41) or 200D SMA ($156.72) invalidates the momentum regime and cuts Target Base ($188.73) toward Bear Floor ($147.21).
Revolution Medicines Inc. (RVMD) advanced +0.55% to $191.31, trading at 80% of its 52-week range ($56.66 – $224.31). Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance Australia report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
The Motley Fool report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
Stocks Down Under report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
Investor's Business Daily report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
Ten stocks carry implied earnings moves above 10% next week, led by Moderna and AppLovin. Five are tech names hit in Friday's chip rout.
Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and P
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +15.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RVMD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RVMD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Revolution Medicines Inc. (RVMD) ranks #222 by composite RQD confidence (55/100, grade D+) and #47 by equity capitalization ($40.78B). Within this direct 5-issuer industry benchmark cohort, BIIB leads on earnings valuation at 28.5x trailing P/E, while ARGX leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. BIIB currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with RVMD at 55/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RVMD
ACTIVE
Revolution Medicines Inc. | D+ | 55/100 | — | — | -28.6% | +0.55% | $40.78B | Benchmark Subject |
| BIIB Biogen Inc. | B | 74/100 | 28.5x | 75.7% | 6.4% | +1.59% | $36.90B | /biib-vs-rvmd → |
| ARGX argenx SE | C | 63/100 | 32.8x | — | 9.9% | -0.56% | $55.72B | /argx-vs-rvmd → |
| BNTX BioNTech SE | D+ | 52/100 | 32.8x | — | 9.9% | -1.08% | $22.39B | /bntx-vs-rvmd → |
| MRNA Moderna Inc. | C- | 60/100 | — | 55.3% | -34.1% | -0.47% | $88.93B | /mrna-vs-rvmd → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Revolution Medicines Inc. (RVMD) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$1.13B, operating cash flow of -$897.7M, and free cash flow of -$913.7M (-60.9% YoY). On the balance sheet, RVMD closed FY2025 with $2.35B in total assets against $325.4M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$1.13B | -$897.7M | -$913.7M | $2.35B | $325.4M |
| FY2024 (FY) | 2024-12-31 | $0 | -$600.0M | -$557.4M | -$567.7M | $2.56B | $131.9M |
| FY2023 (FY) | 2023-12-31 | $11.6M | -$436.0M | -$350.6M | -$351.1M | $22.43B | $5.25B |
As of 2026-11-02, Revolution Medicines Inc. (NASDAQ: RVMD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $191.31 (+0.55% 1D, market cap $40.78B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RVMD ranks #222 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), RVMD carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.6%. By comparison, BIIB (Biogen Inc.) holds a B grade (74/100 RQD, P/E 28.5x, ROIC 6.4%, cap $36.90B) and ARGX (argenx SE) posts a C grade (63/100 RQD, P/E 32.8x, ROIC 9.9%, cap $55.72B). Among the 5-stock peer group, BIIB leads on earnings multiple (28.5x) while ARGX leads on capital efficiency (9.9% ROIC).
Per RVMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001628171), Revolution Medicines Inc. generated $0 in revenue, -$1.13B in net income, and -$913.7M in free cash flow against $2.35B in total assets and $325.4M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
RVMD last traded at $191.31 (+0.55% on volume of 1,100,758 shares), positioning the stock -3.58% below its 50-day simple moving average ($198.41) and +22.07% above its 200-day simple moving average ($156.72). Across its 52-week range of $56.66 to $224.31, RVMD sits at the 80.3% percentile with a 14-day RSI of 47.8 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($173.14 to $209.48).
Why RVMD Stock advanced +0.55% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
The Roarable RQD rating is 55 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim" (per the Roarable RQD rating). The score is built from five pillars:
For a prospective investor evaluating the stock today, the rating points to a clear tension: the balance sheet metrics are comparatively supportive, while the cash-generation, insider, and returns metrics are weak. Upside drivers would need to come from improvement in cash generation or returns on capital, which the source data does not project. Valuation tradeoffs are visible in the fact that forward P/E is 34 while trailing EPS is negative (per the Market Data section), meaning current pricing relies on expectations not captured in the reported figures. This is an analytical summary, not personalized financial advice.
Revolution Medicines Inc. (RVMD) is a NASDAQ-listed company in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry (per the company profile). The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M for FY 2025 and FY 2024 and $11.6M for FY 2023 (per the SEC financials). Market capitalization is $40.8B (per the company profile).
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-1182.4M | $-1131.0M | N/A | $-913.7M | $383.7M | $325.4M |
| FY 2024 | $0.0M | $-689.5M | $-600.0M | N/A | $-567.7M | $543.1M | $131.9M |
| FY 2023 | $11.6M | $-487.2M | $-436.0M | N/A | $-351.1M | N/A | $5248.6M |
Per the SEC financials, the company reported operating losses in each period shown, and reported margins are 0% for gross, operating, and net (per the Market Data section). Per the Roarable RQD rating, ROIC is -28.6% and the Altman Z-Score is 26, with a Piotroski F-Score of 5/9. Debt/Equity is 0.19 (per the Roarable RQD rating). Reported debt declined from $5248.6M in FY 2023 to $325.4M in FY 2025 per the SEC financials, while cash was $383.7M at FY 2025 year-end.
Per the recent news feed, six items were published covering RVMD, all tagged with a YELLOW signal light under the MARKET WIRE label. Headlines reference market action, a 7.41% move on Oct 20 (per TradingKey), a report describing the company as "Its Already The Most Advanced RAS Company And There's More To Come" (per Stocks Down Under), and a question about whether the stock is a "millionaire-maker" (per The Motley Fool). The news summaries are generic and do not provide specific catalyst details such as trial results, approvals, or partnerships. Risk watch items are not specified in the source data. The butterfly supply-chain graph contains no proprietary signals (per the Butterfly Supply-Chain Graph).
Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links or proprietary signals. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are not available in source data. Sector classification is Health Care (per the company profile).
Real-time company headlines, analyst actions, and sector developments for Revolution Medicines Inc. (RVMD) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Australia report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
The Motley Fool report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
Stocks Down Under report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
Investor's Business Daily report covering Revolution Medicines Inc. (RVMD) market action, institutional positioning, and fundamental catalysts.
Welcome to the RVMD (Revolution Medicines Inc.) Roar Pit. Current RQD Composite is 55/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on RVMD, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Revolution Medicines Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on RVMD, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $190.27 (52-wk range $56.66 - $224.31), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).